novozymes
(3)
Matt Eiswerth Makes Biology Move
His career has crossed factories, consumer brands and a growth-stage company. At Novonesis, the common thread is the quiet discipline of turning plans into products customers can count on.
The Danish Company Betting That Microbes Can Do What Chemistry Can't
Novozymes and Chr. Hansen spent a century turning bacteria and enzymes into industrial ingredients. In 2024 they became one company - and quietly one of the biggest biotech businesses you have never heard of.
Ajay Kshatriya
Ajay Kshatriya is the CEO and co-founder of Aizen Therapeutics, a San Diego biotech that spun out of Caltech to build 'Mirror Peptides' - drugs made entirely of D-amino acids, the mirror image of the proteins nature uses. The company launched from stealth in November 2024 with $13M and a generative-AI platform called DaX. Before Aizen, Ajay founded and ran Biota, an environmental genomics company acquired by Novozymes in 2021 after creating roughly $400M in economic value and saving 1.2 billion gallons of water for industrial clients. A UC Berkeley and Stanford-trained chemical engineer who began his career at Genentech and learned company-building as a seed investor at XSeed Capital, he now also invests in Caltech science startups as a partner at Wilson Hill Ventures.